Vendor Intelligence Report: TCI

Published 14 Jun 2026. 21-page investigative report on who is behind TCI: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

TCI is a Telegram-first peptide vendor with a small but uneven Finnrick record. Across 4 Finnrick lab tests, TCI posts 3 pass / 1 fail, a 75% overall pass rate. The current data supports a product-specific read, not a brand-wide verdict: Retatrutide is the stronger tested line, while Tesamorelin splits its limited record and should not be treated as equivalent.

One passing Retatrutide sample still carries an underfill caveat, and the full methodology-divergence chart shows how ratings move as fill tolerances tighten. The quality story is only half the report: the investigated web stack connects the Finnrick-listed Telegram channel to tjcangtu.com and a Made-in-China surface for Tianjin Cangtu, but the legal trail is not clean.

The most severe non-lab issue is the catalog. Captured TCI pages place peptides in the same environment as Etodesnitazene, opioid-analog and benzodiazepine listings, and precursor-category chemicals. That does not prove a completed sale of those substances, but it changes the counterparty-risk picture for a peptide buyer: enforcement disruption, customs scrutiny, payment disruption, and supplier-contamination risk become part of the decision.

TCI also has a reputation problem that purity numbers cannot resolve. Forum materials describe premium pricing and clinical grade praise, but also a reported sterility-test failure that this dossier does not convert into a Finnrick sterility result. Because Finnrick’s current record does not establish sterility or endotoxin status, the report treats batch-specific COA verification and independent testing as practical controls, especially for untested products.

Inside the full report:

  • Appendix A lab table and methodology-divergence charts for both tested products
  • Telegram, tjcangtu.com, Made-in-China, and copied Shanxi Leefu-Bio identity evidence
  • Captured catalog pages including Etodesnitazene and precursor-category listings
  • WHOIS, IP, hosting, and reverse-IP analysis for TCI’s web infrastructure
  • Sterility and community-reputation review, including the affiliate-promotion scan and its coverage gaps

Risk assessment

  • Controlled-substance catalog and law-enforcement disruption risk — high: tjcangtu.com lists Etodesnitazene, a DEA Schedule I synthetic opioid, alongside opioid analogs, benzodiazepines, and drug-precursor categories.
  • Sterility and endotoxin assurance risk — high: Finnrick’s current TCI record does not establish sterility or endotoxin status, and field-captured forum reporting alleged a prior TCI sterility-test failure.
  • Corporate transparency and channel-verification risk — medium: Ownership could not be cleanly verified; TCI’s about-page text matches Shanxi Leefu-Bio, exact Chinese-registry searches were thin, and no official-channel / anti-counterfeit system was documented.
  • Product-specific quality-control risk: Tesamorelin — medium: Tesamorelin is the weak tested product in Finnrick’s current TCI record: 2 tests, 1 pass, 1 fail, and a 44.48% rating.